Nutraceutix acquires exclusive rights to drug delivery patent

25-Sep-2001

25 Sep 2001

Nutraceutix Inc., has acquired a license for pharmaceutical applications for the first CDT Controlled Delivery Technology patent from Temple University School of Pharmacy, Philadelphia.

This new U.S. license grants exclusive rights to develop, manufacture and sell prescription oral dosage forms of drugs, as well as OTC products, and dietary supplements as previously licensed to Nutraceutix. Developed in the laboratories of Dr. Reza Fassihi, Ph.D., at Temple, the second CDT patent (U.S. pat. No. 6,090,411) was licensed exclusively to Nutraceutix in September 2000 for pharmaceutical, OTC, and nutraceutical applications.

The platform of CDT technologies may signal a milestone in delivery technology science as they address many of the challenges common to delivery systems that are currently available. The new technology has been shown to be rugged and robust during in-vitro studies on a wide range of established pharmaceuticals, such as nifedipine, theophylline, propanolol, diltiazem, and verapamil, as well as OTC and nutritional supplements such as pseudoephedrine, glucosamine and niacin.

According to David T. Howard, president & CEO of Nutraceutix Inc., "The U.S. patent for pharmaceutical applications provides Nutraceutix with a clear technological advantage over first generation, controlled delivery systems. Now, complementing our existing alliances with OTC and nutraceutical companies, we will seek to partner with major pharmaceutical and generic companies as well, to co-develop new prescription drugs incorporating Nutraceutix's technology."

The underlying technical principles of the developed technologies are sound. Drug delivery and the system can be optimally manipulated to meet many of the challenges of the next decade that we face in life- cycle management of both old and new drugs. Formulation flexibility of the developed systems lends itself to easy production of a larger range of dose variants for elderly patients and individualized dosage regimens.

https://www.chemeurope.com/en/news/4916/nutraceutix-acquires-exclusive-rights-to-drug-delivery-patent.html